SCM
Sio Capital Management Portfolio holdings
AUM
$249M
This Quarter Return
+21.98%
1 Year Return
+117.71%
3 Year Return
+238.99%
5 Year Return
+411.91%
10 Year Return
+912.87%
AUM
$287M
AUM Growth
+$287M
(-26%)
Cap. Flow
-$129M
Cap. Flow
% of AUM
-44.88%
Top 10 Holdings %
Top 10 Hldgs %
58.33%
Holding
64
New
21
Increased
4
Reduced
11
Closed
12
Top Buys
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$13.6M |
| 2 |
Labcorp
LH
|
$13.3M |
| 3 |
Medtronic
MDT
|
$9.15M |
| 4 |
Organon & Co
OGN
|
$9.01M |
| 5 |
Tyra Biosciences
TYRA
|
$8.79M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$85.3M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
$50.2M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$19.1M |
| 4 |
United Therapeutics
UTHR
|
$17.6M |
| 5 |
Cigna
CI
|
$14.7M |
Sector Composition
| 1 | Healthcare | 99.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Labcorp
LH
$23.1B
| $49.4M | 14.69% | 225,902 +60,779 | +37% | +$13.3M |
|
|
2
Cigna
CI
$80.3B
| $27.6M | 8.23% | 76,086 -40,467 | -35% | -$14.7M |
|
3
Globus Medical
GMED
$8.27B
| $21.1M | 6.28% | 393,420 -138,669 | -26% | -$7.44M |
|
|
4
Madrigal Pharmaceuticals
MDGL
$9.76B
| $13.6M | 4.06% | +51,000 | New | +$13.6M |
|
5
GSK
GSK
$79.9B
| $11.3M | 3.36% | 263,445 -307,946 | -54% | -$13.2M |
|
6
Zimmer Biomet
ZBH
$21B
| $9.79M | 2.92% | 74,179 +1,879 | +3% | +$248K |
|
|
7
Medtronic
MDT
$119B
| $9.15M | 2.72% | +105,000 | New | +$9.15M |
|
|
8
Organon & Co
OGN
$2.45B
| $9.01M | 2.68% | +479,023 | New | +$9.01M |
|
|
9
Tyra Biosciences
TYRA
$675M
| $8.79M | 2.62% | +535,741 | New | +$8.79M |
|
10
Embecta
EMBC
$847M
| $7.77M | 2.31% | 585,418 -150,590 | -20% | -$2M |
|
11
Teleflex
TFX
$5.59B
| $7.66M | 2.28% | 33,878 -2,649 | -7% | -$599K |
|
12
Arcutis Biotherapeutics
ARQT
$1.86B
| $6.3M | 1.88% | 635,969 | – | – |
|
13
BridgeBio Pharma
BBIO
$9.89B
| $6.28M | 1.87% | 203,174 +71,421 | +54% | +$2.21M |
|
14
Humacyte
HUMA
$245M
| $6.22M | 1.85% | +2,000,000 | New | +$6.22M |
|
15
ANI Pharmaceuticals
ANIP
$2.03B
| $6.04M | 1.8% | +87,354 | New | +$6.04M |
|
16
Astria Therapeutics
ATXS
$349M
| $5.77M | 1.72% | +410,267 | New | +$5.77M |
|
17
ARS Pharmaceuticals
SPRY
$1.15B
| $5.48M | 1.63% | 536,163 -569,748 | -52% | -$5.82M |
|
18
Healthcare Services Group
HCSG
$1.13B
| $5.26M | 1.57% | 421,317 -388,990 | -48% | -$4.85M |
|
19
Apogee Therapeutics
APGE
$2.17B
| $5.18M | 1.54% | +78,000 | New | +$5.18M |
|
|
FUSN
20
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $5.18M | 1.54% | 243,035 -3,001 | -1% | -$64K |
|
21
Erasca
ERAS
$445M
| $5M | 1.49% | +2,427,184 | New | +$5M |
|
22
X4 Pharmaceuticals
XFOR
$84.3M
| $4.99M | 1.49% | 3,588,427 | – | – |
|
23
Nuvation Bio
NUVB
$1.02B
| $4.86M | 1.45% | +1,336,231 | New | +$4.86M |
|
24
Scholar Rock
SRRK
$3.14B
| $4.86M | 1.45% | +273,720 | New | +$4.86M |
|
25
Integra LifeSciences
IART
$1.18B
| $4.86M | 1.45% | +137,000 | New | +$4.86M |
|